NVAX at the crossroad

NVAX had some headwinds news with the small set back on the 2nd stage clinical trial. The 15% drop landed the NVAX at the bottom of the trend line, a confirmed break below low (below 10$ for 2+ trading days) would be a strong sell signal, or a potential rebounded to the up trendline with more support of debunking the allegation.